Is Nitropaste Effective in Stressed Flaps?

ABSTRACT: Topical nitroglycerine (nitropaste) is an agent that has seen popularization in plastic surgery in recent years. A low-cost medication functioning, by inducing vasodilation primarily in the venous system and inhibiting platelet aggregation, has shown the ability to provide benefits in clinically concerning skin flaps. In random-pattern skin flaps, research shows that topical nitroglycerine decreases flap loss and increases the percentage of viable tissue. In mastectomy skin flaps, there have been multiple studies showing significant decreases in flap necrosis and need for debridement in patients undergoing topical nitroglycerine application without changes in complications profiles. These studies have included patients undergoing and not undergoing implant-based breast reconstruction. There are no data examining myocutaneous or perforator flaps. In free flaps, there is research showing benefit of nitroglycerine in breaking vasospasm and inducing vasodilation in microsurgery. Overall, topical nitroglycerine is a proven entity effective at increasing viable tissue in random-pattern skin flaps and shows clear benefits in the reduction of mastectomy skin flap necrosis with minimal adverse effects or additional cost. Further research is needed into other areas of plastic surgery where it may be of value.

Effectiveness of Liposomal Bupivacaine Transversus Abdominis Plane Block in DIEP Flap Breast Reconstruction: A Randomized Controlled Trial.

BACKGROUND: Transversus abdominis plane (TAP) blocks improve pain control and reduce narcotic medication requirements in various surgical procedures. Liposomal bupivacaine may provide more sustained analgesia. This study compared pain-related outcomes between standard bupivacaine and liposomal bupivacaine TAP blocks after autologous breast reconstruction. METHODS: The authors conducted a single-center, single-blinded randomized controlled trial between March of 2021 and December of 2022. Patients undergoing deep inferior epigastric perforator flap breast reconstruction in a standardized enhanced recovery after surgery pathway were randomized to receive intraoperative TAP blocks with either bupivacaine and epinephrine (control group) or liposomal bupivacaine, bupivacaine, and epinephrine (experimental group). Primary outcome was postoperative narcotic medication requirements, with secondary outcomes of pain scores, length of stay, and narcotic medication refills. RESULTS: A total of 117 patients met inclusion criteria (59 control patients and 58 experimental patients). Demographic characteristics, comorbidities, breast pathologic variables, surgery laterality, and immediate versus delayed reconstruction status were equivalent between groups. The control group had significantly higher average pain scores postoperatively (4.3 versus 3.6; P = 0.004). However, there were no significant differences in mean narcotic use (66.9 morphine milligram equivalents versus 60.2 morphine milligram equivalents; P = 0.47). Both length of stay and postoperative narcotic prescription refills were equivalent between groups (2.1 days versus 2.2 days, P = 0.55; 22% versus 17.2%, P = 0.52). CONCLUSIONS: The addition of liposomal bupivacaine to the standard bupivacaine TAP block mixture in a standardized enhanced recovery after surgery protocol did not demonstrate a significant reduction in postoperative narcotic requirements after deep inferior epigastric perforator flap breast reconstruction compared with standard bupivacaine alone. Patient-reported pain scores, however, were lower among liposomal bupivacaine patients after the initial 24 hours postoperatively and consistent with a longer duration of analgesia. CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, II.

Optimizing perioperative outcomes in autologous breast reconstruction.

Perioperative optimization in surgery is paramount to the success of an operation. This especially applies to autologous breast reconstruction where small details can make the difference between success and failure. In this article, the authors discuss a wide array of aspects of perioperative care in autologous reconstruction and best practices. Stratification of surgical candidates, including types of autologous breast reconstruction are discussed. The informed consent process, including benefits, alternatives, and risks specific to autologous breast reconstruction is delineated. The importance of operative efficiency and benefits of pre-operative imaging are discussed. The importance and benefits of patient education is examined. Also examined at length are pre-habilitation and its effects on patient recovery, antibiotic prophylaxis including duration and organism coverage, venous thromboembolism risk stratification and prophylaxis, anesthetic and analgesic interventions including multiple types of regional blocks are broken down. Flap monitoring methods and the importance of clinical exam are emphasized, and the potential risks of blood transfusion in free flap patients are examined. Post-operative interventions and determining readiness for discharge are also reviewed. The review of these components of perioperative care allows the reader to gain comprehensive insight into autologous breast reconstruction best practices and the important role perioperative care plays in this patient population.